Royalty Pharma plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $452.0M | $2.0M | $52.0M | $177.1M | $200.1M | $26.3M | $83.0M | $392.6M |
| SG&A Expense | $573.5M | $236.7M | $249.7M | $227.3M | $182.8M | $181.7M | $103.4M | $61.9M |
| Operating Income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B | $1.60B | $2.62B | $1.36B |
| Operating Margin | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% | 75.2% | 144.6% | 76.0% |
| Interest Expense | — | — | $187.2M | $188.0M | $166.1M | $157.1M | $268.6M | $280.0M |
| Pretax Income | $1.32B | $1.33B | $1.70B | $230.1M | $1.24B | $1.70B | $2.46B | $1.52B |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M | $975.0M | $2.35B | $1.38B |
| Net Margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% | 45.9% | 129.4% | 76.8% |
| EPS (Basic) | $1.79 | $1.92 | $2.54 | $0.10 | $1.49 | $1.32 | — | — |
| EPS (Diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — | — |
| Shares Outstanding (Basic) | 429.8M | 448.2M | 447.6M | 438.0M | 414.8M | 375.4M | — | — |
| Shares Outstanding (Diluted) | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M | 375.5M | — | — |
| Dividends Per Share | — | $0.84 | $0.80 | $0.76 | $0.68 | $0.30 | — | — |